2016

A patent related to the Liungman Guidewire Fixator developed by Endovab was recently granted by JPO, the Japanese patent office. The unique anchoring feature of the device effectively prevents loss of guidewire position. Distal guidewire fixation also enables fundamentally new guidewire techniques, since the proximal end can be manipulated without loosing the distal position.
 
“A long term IP strategy is essential for research and development companies, especially when developing ‘first in category’ products like Endovab” says Linus Bosaeus, CEO Endovab. 

Read the full post »

This years Veith conference was a very exiting event. There was great interest from American colleagues on the LGF approach. There seems to be room for improvement on the existing fenestrated techniques available today. To see the LGF presentation slides please click here. Finally we like to thank Frank Veith and the organizers for a good and diverse conference.

Read the full post »

Increased awareness of risks associated with radiation exposure to surgical staff challenge current endovascular methods for treatment of complicated aortic aneurysms.

A retrospective cohort study of 63 EVAR and 63 f/b-EVAR from 2012-2015 at Uppsala University shows that f/b-EVAR procedures are far more complex than conventional EVAR. 
 

The study result shows a remarkably linear relation between number of branched vessel catheterisations and parameters such as use of fluoroscopy, blood-loss, need for intensive care, and anaesthesia and procedure duration. For example, a complete two-vessel f-EVAR lasts on average for 359 minutes (5h 59min), uses 72 minutes of fluoroscopy, and has a total blood loss of 1100ml. Each additional branch catheterisation equals an average of another 98 minutes (1h 38min) procedure duration, 27 minutes of fluoroscopy and 400ml of blood loss.

 

More about this and the LGF approach to reduce the f/b-EVAR challenges will be presented at the Veith Symposium in New York. Wednesday the 15th of November at 10:42, session 41 in the Trianon Ballroom Hilton Hotel.

Read the full post »

Endovab announced today that it has received CE mark approval for the Liungman Guidewire Fixator, the LGF™.
 
"This is a major landmark for our company and the development of endovascular techniques in general. The LGF is the first ever guidewire that can be anchored distally in an artery while maintaining blood flow. Distal fixation allows parallel work and a range of new endovascular methods and techniques, such as improve the treatment of complicated aortic aneurysms by reducing procedure duration and make more patients eligible for treatment. It also has the added benefit of making procedures more predictable, saving hospitals time and resources” states Linus Bosaeus, CEO of Endovab.
 
Endovab is a medical device development company, founded by vascular surgeon and inventor MD PhD Krister Liungman, former Head of Vascular Surgery at Uppsala University Hospital. The concept of the LGF was initiated after a lifelong career in aortic repair, with the vision to improve endovascular treatment of complicated aortic aneurysms, and a way for the surgeons to maintain guidewire position at all times.
 
The LGF consists of a braided structure of Nickel Titanium, a super elastic memory alloy, which secures the guidewire position through a moderate radial force to the vessel wall. If tension is applied to the guidewire, the braided structure deforms and increases the radial force temporarily to maintain guidewire position, a built-in safety feature prevents over expansion and arterial trauma.
 
The LGF is a really interesting and innovative product that enables new working methods that will improve treatment and push the endovascular frontiers further”, states Professor Anders Wanhainen from Uppsala University, principal investigator for the clinical study.  Scientific board member and thoracic surgery expert professor Tilo Koelbel from the Heart Center in Hamburg comments “Endovab truly has a great team and their disruptive innovation is really impressive in this competitive filed of medical technology”.
 
Over the coming months, the company will introduce the LGF to specialized endovascular clinics for further studies in the field of endovascular aortic repair.
 
Press contact: Linus Bosaeus, linus.bosaeus@endovab.com +46760199975 
Click here to down load the full text: 

Read the full post »

Thank you ESVS for the opportunity and all you innovative surgeons who engaged us afterwards. More information regarding the guidewire fixator and the facilitated method for f/b-EVAR can be found here.  

Read the full post »

The procedure duration and the use of flouroscopy diffrence is significant between EVAR and f-EVAR. These are the early result from an ongoing study at Uppsala University Hospital, Sweden. How can this be adressed? Dr Krister Liungman belives that pre-lined stantgrafts together with Guidewire Anchors might be the solution to trim lengthy f-EVAR procedures and radiation exposure. Please visit Dr Liungmans presentation at the ESVS conference in Copenhagen the 28th of September at 11.15 in the Congress Hall during Scientific Session 1 - Thoracic Aorta.

Read the full post »

As an innovative development company, Endovab seeks to improve and develop endovascular procedures. A step-by-step description research paper of the new method for f/b-EVAR using the Guidewire Fixator is now available for download. All input and comments are appreciated for further improvements and other areas for use.

Read the full post »

Endovab are happy to announce that the clinical investigation for the Liungman Guidewire Fixator (LGF) has been successfully completed. The LGF is a completely new medical device, first of its kind to offer temporarily anchoring of a guidewire in a target artery while maintaining blood-flow.

Professor Anders Wanhainen presents the clinical data from the LGF study and the latest facilitated f/b-EVAR research at the Charing Cross Symposium. The LGF presentation is held in the Olympia Room, at the Innovation Showcase stage on Wednesday the 27th of April at 08.50 - 09.00.
 
Do you want to know more? We will off course be there if anyone likes to see or feel the LGF device. We encourage all feedback from the vascular scientific society so please let us know if you have queries or suggestions regarding the new f/b-EVAR technique.
 

Read the full post »

In this 4 min presentation, originally held during the VEITH conference in 2015, Dr Krister Liungman explains the facilitated f-EVAR method and how anchoring of the guidewires eliminates locating the arterial branched from inside the stentgraft. He also runs through the pre-clinical study results that formed the basis for the ongoing clinical study of the new Guidewire Fixator at Uppsala University Hospital.

Read the full post »

Find the published data from the pre-clinical study here. The study included test of device delivery and retrieval and deposition in the blood stream. As well as investigation of the risks for occlusion, dissection or arterial trauma upon maximum anchoring.

Results show that the anchoring force in the test had an average of 7,6N, please read the full article to find out more about the promising results.  

Read the full post »
Tags: nyheter

Anchoring a guidewire in an artery allows new methods, such as rerouting of the proximal end and pre-cannulated f-EVAR. These methods will be presented at the annual vascular LINC meeting in Leipzig, Germany the 28th of January 11.20-11.25 at Sperakers Corner. Please come and see Dr Krister Liungmans presentation of these innovative opportunities enabled by the first ever Guidewire Fixator.

Read the full post »

ARCHIVE

LATEST NEWS

Copyright © 2019. Endovascular Development AB. All Rights Reserved.